Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | LDHA | P00338 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | LDHB | P07195 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27797214 | 1.00 | P2RX7 (0.46) | P2RX7DPP4KDM4EALDH1A1HSD17B10 | |
| SCHEMBL8132956 | 0.88 | P2RX7 (0.46) | P2RX7 | |
| SCHEMBL27797240 | 0.85 | P2RX7 (0.42) | P2RX7DPP4 | |
| SCHEMBL27797239 | 0.85 | P2RX7 (0.42) | P2RX7DPP4 | |
| SCHEMBL4448219 | 0.85 | P2RX7 (0.47) | P2RX7KDM4ELDHAALBLDHB | |
| SCHEMBL27776447 | 0.83 | P2RX7 (0.51) | P2RX7KDM4EALDH1A1 | |
| SCHEMBL27776449 | 0.83 | P2RX7 (0.51) | P2RX7KDM4EALDH1A1 | |
| SCHEMBL28785678 | 0.82 | P2RX7 (0.48) | P2RX7ALDH1A1 | |
| SCHEMBL28785677 | 0.82 | P2RX7 (0.48) | P2RX7ALDH1A1 | |
| SCHEMBL27776543 | 0.81 | P2RX7 (0.51) | P2RX7F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101686680-A | Bicyclic heteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS INC | 2010-03-31 | — | — | CN | claimed |
| EP-2124562-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | claimed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| EP-2124562-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-04-20 | — | — | EP | disclosed |
| CN-101686680-A | Bicyclic heteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS INC | 2010-03-31 | — | — | CN | disclosed |
| EP-2124562-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2008-11-20 | — | — | US | disclosed |
| WO-2008112205-A1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287415-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885DPP4 1905/4885KDM4E 4307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.